
Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) - Stock analysts at Leerink Partnrs lowered their Q4 2025 earnings per share (EPS) estimates for shares of Lantheus in a research note issued to investors on Tuesday, July 29th. Leerink Partnrs analyst R. Ruiz now expects that the medical equipment provider will post earnings per share of $1.50 for the quarter, down from their prior estimate of $1.51. The consensus estimate for Lantheus' current full-year earnings is $6.01 per share. Leerink Partnrs also issued estimates for Lantheus' FY2026 earnings at $7.08 EPS.
Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the previous year, the business earned $1.69 earnings per share. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year.
A number of other equities research analysts also recently commented on LNTH. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. William Blair reiterated a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Truist Financial lowered their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, B. Riley reduced their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $131.20.
Read Our Latest Research Report on LNTH
Lantheus Trading Down 0.9%
LNTH stock traded down $0.62 during midday trading on Wednesday, reaching $70.57. The company's stock had a trading volume of 943,059 shares, compared to its average volume of 1,017,600. The business's 50-day simple moving average is $77.65 and its 200-day simple moving average is $87.98. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. Lantheus has a 52 week low of $69.12 and a 52 week high of $118.21. The stock has a market cap of $4.88 billion, a PE ratio of 20.05 and a beta of 0.14.
Institutional Investors Weigh In On Lantheus
A number of institutional investors and hedge funds have recently modified their holdings of LNTH. Janus Henderson Group PLC lifted its position in shares of Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after buying an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in Lantheus by 2.2% during the first quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider's stock worth $155,101,000 after purchasing an additional 34,052 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after purchasing an additional 435,445 shares during the period. Finally, Reinhart Partners LLC. raised its position in shares of Lantheus by 16.4% in the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider's stock valued at $114,905,000 after purchasing an additional 197,719 shares during the period. 99.06% of the stock is owned by institutional investors.
Insider Transactions at Lantheus
In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director owned 318,650 shares of the company's stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.50% of the company's stock.
About Lantheus
(
Get Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Read More
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.